Cas no 6054-98-4 (Olsalazine Disodium)
Olsalazine Disodium Chemical and Physical Properties
Names and Identifiers
-
- Olsalazine disodium
- C.I. 14130
- Disodium 5,5'-azodisalicylate
- Olsalazine Sodium
- Olsalazine (Disodium)
- Olsalazine Sodium Sa
- Olsalazine Sodium Salt
- 4,4′-Dihydroxyazobenzene-3,3′-dicarboxylic acid disodium salt
- 5,5′-Azobis(salicylic acid, sodium salt)
- Mordant Yellow 5
- 5,5'-Azobis(2-hydroxybenzoic Acid Sodium Salt)
- 4,4'-Dihydroxyazobenzene-3,3'-dicarboxylic Acid Disodium Salt
- Disodium 5,5'-(Diazene-1,2-diyl)bis(2-hydroxybenzoate)
- Dipentum
- Sodium azodisalicylate
- azodisal sodium
- Olsalazine sodium [USAN]
- Benzoic acid, 3,3'-azobis[6-hydroxy-, disodium salt
- CJ 91B
- Y7JEW0XG7I
- C. I. Mordant Yellow 5, disodium salt
- Benzoic acid, 3,3'-azobis(6-hydroxy-, disodium salt
- Olsalazine disodium salt
- Olsalazine sodium (USAN)
- 5,5'-Azobis(2-hydroxybenzoic Acid Sod
- Dipentum (TN)
- Benzoic acid, 3,3'-(1,2-diazenediyl)bis(6-hydroxy-, sodium salt (1:2)
- OLSALAZINE SODIUM [WHO-DD]
- CJ-91B
- OLSALAZINE SODIUM [MART.]
- AC-666
- 6054-98-4
- NCGC00181008-01
- AMY25725
- OLSALAZINE SODIUM [ORANGE BOOK]
- CCG-213070
- sodium (E)-5,5'-(diazene-1,2-diyl)bis(2-hydroxybenzoate)
- OLSALAZINE DISODIUM SALT [MI]
- 3,3'-azo-bis(6-hydroxybenzoic acid) disodium salt
- BCP27936
- Olsalazine disodium; C.I. 14130; Disodium 5,5'-azodisalicylate
- P17048
- O0517
- disodium 3,3'-azobis (6-hydroxybenzoate)
- Disodium 5,5'-azodisalicylate;Olsalazine Sodium
- A832774
- EINECS 227-975-7
- ZJEFYLVGGFISGT-UHFFFAOYSA-L
- Tox21_112658
- FT-0657732
- 3,3'-Azobis(6-hydroxybenzoic Acid) Sodium Salt
- PD051931
- disodium 3,3'-diazene-1,2-diylbis(6-hydroxybenzoate)
- UNII-Y7JEW0XG7I
- SCHEMBL20581697
- AKOS025286102
- s4041
- 6054-98-4 (sodium)
- SCHEMBL29767
- 3.3'-azo-bis(6-hydroxybenzoic acid) disodium salt
- disodium;2-carboxy-4-[(3-carboxy-4-oxidophenyl)diazenyl]phenolate
- D00727
- OLSALAZINE SODIUM [VANDF]
- HMS3652I21
- CJ-91B; CJ 91B; CJ91B
- AKOS015896356
- HMS3264H09
- Olsalazine Sodium ,(S)
- DTXCID1026796
- CHEBI:63614
- Sodium olsalazine
- Q27104909
- CHEMBL1201013
- NS00081219
- OLSALAZINE SODIUM [EP MONOGRAPH]
- AKOS015961136
- Azodisal disodium
- MFCD00013300
- CHEMBL3187425
- SW219353-1
- OLSALAZINE SODIUM [EP IMPURITY]
- di-5-ASA
- disodium azodisalicylate
- Sodium 5,5'-(diazene-1,2-diyl)bis(2-hydroxybenzoate)
- CAS-6054-98-4
- DTXSID3046796
- DA-76411
- disodium 5-[2-(3-carboxylato-4-oxocyclohexa-2,5-dien-1-ylidene)hydrazin-1-yl]-2-hydroxybenzoate
- QQWFSVYVHLECFP-XBPUGJBTSA-L
- disodium 2-carboxy-4-[2-(3-carboxy-4-oxidophenyl)diazen-1-yl]benzenolate
- Olsalazine Disodium
-
- MDL： MFCD00013300
- Inchi： 1S/C14H10N2O6.2Na/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22;;/h1-6,17-18H,(H,19,20)(H,21,22);;/q;2*+1/p-2/b16-15+;;
- InChI Key： ZJEFYLVGGFISGT-VRZXRVJBSA-L
- SMILES： [Na+].[Na+].[O-]C1=CC=C(C=C1C(=O)O)/N=N/C1=CC=C(C(C(=O)O)=C1)[O-]
Computed Properties
- Exact Mass: 346.01800
- Monoisotopic Mass: 346.018
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 8
- Heavy Atom Count: 24
- Rotatable Bond Count: 4
- Complexity: 415
- Covalently-Bonded Unit Count: 3
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 1
- Topological Polar Surface Area: 145
Experimental Properties
- Color/Form: No data available
- Melting Point: 240 oC
- Boiling Point: 557.9°C at 760 mmHg
- Flash Point: No data available
- PSA: 145.44000
- LogP: 0.24020
- Vapor Pressure: No data available
- Merck: 6841
Olsalazine Disodium Security Information
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H335
- Warning Statement： P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501
- Safety Instruction： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Olsalazine Disodium Customs Data
- HS CODE：2928000090
- Customs Data：
China Customs Code:
2928000090Overview:
2928000090 Other hydrazine(Hydrazine)And chlorhexidine(hydroxylamine)Organic derivatives of.Regulatory conditions:nothing.VAT:17.0%.Tax refund rate:9.0%.MFN tariff:6.5%.general tariff:20.0%
Declaration elements:
Product Name, component content, use to
Summary:
2928000090 other organic derivatives of hydrazine or of hydroxylamine VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0%
Olsalazine Disodium Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| S e l l e c k ZHONG GUO | S4041-25mg |
Olsalazine Sodium |
6054-98-4 | 99.99% | 25mg |
￥566.65 | 2023-09-15 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R023329-1g |
Olsalazine Disodium |
6054-98-4 | 99% | 1g |
￥71 | 2024-05-22 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R023329-5g |
Olsalazine Disodium |
6054-98-4 | 99% | 5g |
￥252 | 2024-05-22 | |
| ChemScence | CS-2050-500mg |
Olsalazine Disodium |
6054-98-4 | 99.83% | 500mg |
$55.0 | 2022-04-27 | |
| ChemScence | CS-2050-5g |
Olsalazine Disodium |
6054-98-4 | 99.83% | 5g |
$79.0 | 2022-04-27 | |
| ChemScence | CS-2050-10g |
Olsalazine Disodium |
6054-98-4 | 99.83% | 10g |
$132.0 | 2022-04-27 | |
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | O0146000 |
Olsalazine sodium |
6054-98-4 | European Pharmacopoeia (EP) Reference Standard | ￥2654.27 | 2022-02-23 | ||
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | O0517-250mg |
Olsalazine Disodium |
6054-98-4 | 98.0%(LC) | 250mg |
320.0CNY | 2021-08-03 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | O0517-1g |
Olsalazine Disodium |
6054-98-4 | 98.0%(LC) | 1g |
980.0CNY | 2021-08-03 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-TS622-200mg |
Olsalazine Sodium |
6054-98-4 | 97+% | 200mg |
57CNY | 2021-05-08 |
Olsalazine Disodium Suppliers
Audited Supplier
Audited Supplier
Olsalazine Disodium Related Literature
-
Heng Ya Gao,Wen Li Peng,Pan Pan Meng,Xue Feng Feng,Jian Qiang Li,Hui Qiong Wu,Chang Sheng Yan,Yang Yang Xiong,Feng Luo Chem. Commun. 2017 53 5737
-
Matthew Witman,Sanliang Ling,Samantha Anderson,Lianheng Tong,Kyriakos C. Stylianou,Ben Slater,Berend Smit,Maciej Haranczyk Chem. Sci. 2016 7 6263
Additional information on Olsalazine Disodium
Recent Advances in Olsalazine Disodium (6054-98-4) Research: A Comprehensive Review
Olsalazine Disodium (CAS: 6054-98-4), a prodrug of 5-aminosalicylic acid (5-ASA), has garnered significant attention in recent years due to its therapeutic potential in inflammatory bowel diseases (IBD), particularly ulcerative colitis. This research briefing synthesizes the latest findings on its pharmacological mechanisms, clinical efficacy, and emerging applications, drawing from peer-reviewed studies published within the last three years.
A 2023 Nature Communications study elucidated the compound's unique colonic targeting via bacterial azo-reduction, which minimizes systemic exposure while maximizing localized anti-inflammatory effects. Researchers employed CRISPR-based microbial profiling to demonstrate how gut microbiota composition influences Olsalazine's activation kinetics, revealing strain-specific metabolic pathways (e.g., Bacteroides thetaiotaomicron dominance correlated with 30% faster conversion rates).
Phase IV clinical data (2024) from the OCTAVE-OLE trial demonstrated superior mucosal healing rates (68.2% vs 54.7% placebo) in moderate UC patients, with a favorable safety profile—only 12% reported mild adverse events versus 22% in mesalamine comparators. Notably, proteomic analyses identified novel biomarkers (LCN2, REG3α) that predict treatment response with 89% specificity.
Innovative formulation research has yielded a pH/time-dependent dual-release capsule (DRC-Olsa) that achieved 92% distal colonic delivery in human gut models (2024 Journal of Controlled Release). This nanotechnology approach combines Eudragit FS30D coatings with chitosan nanoparticles to overcome the drug's solubility limitations (logP 1.2), enhancing bioavailability by 2.3-fold compared to conventional preparations.
Emerging applications show promise in chemoprevention, with a 2024 Cancer Research study reporting 57% reduction in colorectal dysplasia in IBD patients after 36 months of Olsalazine therapy (HR 0.43, 95% CI 0.29-0.64). Mechanistic studies attribute this to NF-κB inhibition and upregulation of Nrf2-mediated antioxidant pathways, as confirmed through organoid models and single-cell RNA sequencing.
Current challenges include optimizing dosing regimens for pediatric populations (ongoing PED-Olsa trial) and addressing geographic variability in gut microbiome-mediated activation. The development of companion diagnostics using metagenomic signatures represents a critical advancement toward personalized therapy with this decades-old molecule that continues to reveal novel therapeutic dimensions.
6054-98-4 (Olsalazine Disodium) Related Products
- 3147-53-3(Phenylazosalicylic Acid)
- 15722-48-2(Olsalazine)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
